Evidence map›Paper›PMID 41226480›Full record

ArticleInternational journal of molecular sciences2025

Evaluation of 2,7-Naphthyridines as Targeted Anti-Staphylococcal Candidates with Microbiota-Sparing Properties.

Anna Wójcicka, Maciej Spiegel, Bartłomiej Dudek, Malwina Brożyna, Adam Junka, Marcin Mączyński

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna WójcickaDepartment of Organic Chemistry and Pharmaceutical Technology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.ORCID 0000-0001-5057-211X
Maciej SpiegelDepartment of Organic Chemistry and Pharmaceutical Technology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.ORCID 0000-0002-8012-1026
Bartłomiej DudekPlatform for Unique Model Application, Division of Translative Technologies, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.
Malwina BrożynaPlatform for Unique Model Application, Division of Translative Technologies, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.ORCID 0000-0001-9520-3377
Adam JunkaPlatform for Unique Model Application, Division of Translative Technologies, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.ORCID 0000-0002-7559-8903
Marcin MączyńskiDepartment of Organic Chemistry and Pharmaceutical Technology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.ORCID 0000-0001-6110-344X

Funding

Wroclaw Medical University SUBK.D090.24.037Wroclaw Medical University SUBZ.D090.25.035
6 · The paper itself

Abstract

The rising resistance of bacterial and fungal strains, particularly in biofilm form, is diminishing the efficacy of available therapies and poses a major threat to human health. This highlights the need for new antimicrobial agents. A review of biological studies has shown that 2,7-naphthyridine derivatives exhibit a wide spectrum of pharmacological properties, including antimicrobial activity, which has contributed to the development of new compounds containing this scaffold. In this work, the obtained compounds were tested to assess their ability to eradicate biofilm formed by selected reference strains of opportunistic pathogens:

Indexed as

Anti-Bacterial AgentsMicrobiotaNaphthyridinesStaphylococcus aureusAnimalsBiofilmsCandida albicansDNA GyraseHumansMicrobial Sensitivity TestsMolecular Docking SimulationPseudomonas aeruginosaAnti-Bacterial AgentsDNA GyraseNaphthyridines2,7-naphthyridinesantimicrobial activitycytotoxicitymolecular dynamics simulations

Identifiers

PMID41226480
PMCPMC12609412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.